QIAGEN powered by

Webinars and events

Loading Events

« All Events

  • This event has passed.

Accéder rapidement à une connaissance exhaustive pour l’interprétation des variants somatiques avec HSMD

March 30, 2023 @ 10:00 am - 11:00 am

L’interprétation et la classification des variants somatiques demeurent un challenge alors que le nombre de gènes testés continue d’augmenter faisant apparaitre de nouvelles altérations. Ces nouveaux variants dont l’impact clinique est encore inconnu nécessitent une recherche d’information croisée à partir de nombreuses sources. Déterminer la classification d’un variant peut donc s’avérer longue et fastidieuse. La base de variants somatiques HSMD est une ressource en ligne qui vous permet rapidement et en toute confiance de classer vos nouveaux variants. En effet, HSMD contient plus de 300 000 cas en oncologie clinique et plus de 1,5 millions de mutations et leurs données associées, manuellement capturées et intégrées dans la base de connaissance QIAGEN. Le profil mutationnel de gènes d’intérêt, les gènes fréquemment mutés dans une pathologie donnée, l’actionnabilité d’un gène ou encore les essais cliniques pour un cancer ou un traitement spécifique sont des requêtes que les utilisateurs d’HSMD peuvent effectuer simplement. Vous découvrirez lors de ce webinaire comment utiliser HSMD pour votre routine clinique ou dans un cadre de recherche translationnelle.

On-demand Webinars


  • Supercharge your AI in drug discovery with high-quality biomedical data

    If you’re working in pharma or biotech, you likely rely on artificial intelligence (AI) to help you identify new drug targets or plausible biomarkers for disease within large data sets. Yet AI alone isn’t enough. A large proportion of Biomedical data have errors and are unstructured. For AI models to provide reliable insights, the underlying data must be of ‘hig...

  • Scale up NGS bioinformatics analysis throughput with QIAGEN CLC Genomics cloud computing

    Scale your NGS analysis to match your sequencing throughput using our QIAGEN CLC Genomics cloud solution. In this webinar, you’ll learn about the flexible and powerful setup for running your NGS sequence analyses on Amazon Web Services (AWS). You’ll learn how to use QIAGEN CLC Genomics Workbench to customize workflows and send analyses to AWS Batch for execution. ...

  • QIAGEN Biomedical Knowledge Base: Data- and analytics-driven drug discovery

    Biomedical relationships knowledge is now required for innovative data- and analytics-driven drug discovery. It powers biomedical knowledge graph analysis, artificial intelligence (AI)-driven target identification and many more applications. In this one-hour training, you’ll get an introduction to QIAGEN Biomedical Knowledge Base. You’ll learn how to tackle appli...

  • Part 1: AI-Powered Hereditary Disease Diagnostics: Closing the Gap in Clinical Exome Completeness

    Clinical exome sequencing (CES) is increasingly being adopted by small and mid-sized laboratories to diagnose genetic diseases, aid treatment decisions, and provide prognostic information. However, the exponential increase in genetic data generated from exome and genome panels poses significant workflow challenges. The ability to prioritize potentially pathogenic vari...

  • A breakthrough for rare disease: Completing the Clinical exome gap!

    In its latest release, QCI Interpret for Hereditary extends its market-leading content with further advancements in Artificial Intelligence (AI) for enhanced capabilities in clinical exome NGS testing. Now, with the addition of AI-derived literature references for rare disease genes, QCI Interpret provides complete exome coverage, on top of the existing unrivalled man...

  • What’s new in QIAGEN IPA Fall Release 2023?

    Interested in learning about new features and functionalities that have been added to IPA lately? During this webinar, we will highlight the updates from the QIAGEN IPA Fall Release and from previous releases from this year. Topics, amongst others, will be • Newly added findings and pathways • Reactome pathways • Artificial intelligence approves to pathways ...